Accessibility Statement Skip Navigation
  • Resources
  • Blog
  • Journalists
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All News Releases
      • All Public Company
      • English-only
      • News Releases Overview

      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
      • Multimedia Gallery Overview

      • Trending Topics

      • All Trending Topics
  • Business & Money
      • Auto & Transportation

      • All Automotive & Transportation
      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • Auto & Transportation Overview

      • View All Auto & Transportation

      • Business Technology

      • All Business Technology
      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • Business Technology Overview

      • View All Business Technology

      • Entertain­ment & Media

      • All Entertain­ment & Media
      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • Entertain­ment & Media Overview

      • View All Entertain­ment & Media

      • Financial Services & Investing

      • All Financial Services & Investing
      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • Financial Services & Investing Overview

      • View All Financial Services & Investing

      • General Business

      • All General Business
      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • General Business Overview

      • View All General Business

  • Science & Tech
      • Consumer Technology

      • All Consumer Technology
      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • Consumer Technology Overview

      • View All Consumer Technology

      • Energy & Natural Resources

      • All Energy
      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • Energy & Natural Resources Overview

      • View All Energy & Natural Resources

      • Environ­ment

      • All Environ­ment
      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • Environ­ment Overview

      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • All Heavy Industry & Manufacturing
      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • Heavy Industry & Manufacturing Overview

      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • All Telecomm­unications
      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • Telecomm­unications Overview

      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • All Consumer Products & Retail
      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • Consumer Products & Retail Overview

      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • All Entertain­ment & Media
      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • Entertain­ment & Media Overview

      • View All Entertain­ment & Media

      • Health

      • All Health
      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • Health Overview

      • View All Health

      • Sports

      • All Sports
      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • Sports Overview

      • View All Sports

      • Travel

      • All Travel
      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • Travel Overview

      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • All Policy & Public Interest
      • Advocacy Group Opinion
      • Animal Welfare
      • Congressional & Presidential Campaigns
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • U.S. State Policy
      • Policy & Public Interest Overview

      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • All People & Culture
      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • People & Culture Overview

      • View All People & Culture

      • In-Language News

      • Arabic
      • español
      • português
      • Česko
      • Danmark
      • Deutschland
      • España
      • France
      • Italia
      • Nederland
      • Norge
      • Polska
      • Portugal
      • Россия
      • Slovensko
      • Suomi
      • Sverige
  • Overview
  • Distribution by PR Newswire
  • AI Tools
  • Multichannel Amplification
  • Guaranteed Paid Placement
  • SocialBoost
  • All Products
  • General Inquiries
  • Editorial Bureaus
  • Partnerships
  • Media Inquiries
  • Worldwide Offices
  • Hamburger menu
  • PR Newswire: news distribution, targeting and monitoring
  • Send a Release
    • ALL CONTACT INFO
    • Contact Us

      888-776-0942
      from 8 AM - 10 PM ET

  • Send a Release
  • Client Login
  • Resources
  • Blog
  • Journalists
  • RSS
  • News in Focus
    • Browse All News
    • Multimedia Gallery
    • Trending Topics
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Client Login
  • Resources
  • Blog
  • Journalists
  • RSS
  • Overview
  • Distribution by PR Newswire
  • AI Tools
  • Multichannel Amplification
  • SocialBoost
  • All Products
  • Send a Release
  • Client Login
  • Resources
  • Blog
  • Journalists
  • RSS
  • General Inquiries
  • Editorial Bureaus
  • Partnerships
  • Media Inquiries
  • Worldwide Offices
  • Send a Release
  • Client Login
  • Resources
  • Blog
  • Journalists
  • RSS

Johnson & Johnson lança apelo em busca de ideias inovadoras para reduzir a infecção do vírus HIV na África Subsaariana
  • India - English
  • Latin America - español
  • USA - español
  • USA - Deutsch
  • USA - Français
  • USA - English

Parceiros da iniciativa DREAMS anunciam o desafio em busca de inovação no valor de $85 milhões com foco em soluções para meninas adolescentes e jovens adultas


News provided by

Johnson & Johnson

Feb 17, 2016, 05:19 ET

Share this article

Share toX

Share this article

Share toX

NEW BRUNSWICK, Nova Jersey, 17 de fevereiro de 2016 /PRNewswire/ -- A Johnson & Johnson (NYSE: JNJ) lançou um apelo hoje solicitando ideias inovadoras para o Desafio em Busca de Inovação DREAMS, apoiado pelo Plano de Emergência do Presidente dos EUA para o Combate à AIDS (PEPFAR), pela Janssen Pharmaceutica, NV, uma das empresas farmacêuticas Janssen da Johnson & Johnson e pela ViiV Healthcare. Estão sendo aceitas propostas de avanços inovadores para a redução de infecções pelo HIV em meninas adolescentes e jovens nos 10 países da África Subsaariana. O prazo de apresentação para que a proposta seja considerada para premiação é 28 de março de 2016.

Foto - http://photos.prnewswire.com/prnh/20160216/333964

O total de $85 milhões será concedido às soluções inovadoras e sustentáveis para seis áreas de foco do Desafio que proporcionarão às jovens a oportunidade de viver a vida Determinada, Resiliente, Em poder, sem AIDS, Monitorada e Segura que merecem. As soluções vencedoras devem demonstrar prontidão para rápida implementação em um ou mais dos 10 países da iniciativa DREAMS e a habilidade de causar impacto em dois anos e o potencial de mudanças a longo prazo.

"Acreditamos que as descobertas inovadoras necessárias para reduzir as infecções pelo vírus HIV em meninas adolescentes e jovens adultas podem vir de qualquer parte do mundo", disse Dr. Paul Stoffels, médico, diretor científico e presidente global, área farmacêutica da Johnson & Johnson. "Ao patrocinar o Desafio em Busca de Inovação DREAMS temos a esperança de desencadear novas ideias que nos ajudem a atingir, até o final de 2017, uma redução de 40 por cento nos casos de infecção por HIV entre meninas adolescentes e jovens vivendo nos 10 países subsaarianos."

A AIDS é a principal causa de mortalidade entre mulheres em idade reprodutiva em países de renda baixa e média. Meninas adolescentes e jovens representam 380.000 novos casos de infecção por ano ou acima de 7.000 novos casos por semana globalmente.

"Embora tenhamos feito um progresso considerável na resposta global ao HIV/AIDS, meninas adolescentes e jovens não foram, em grande parte, consideradas", disse a embaixatriz Deborah L. Birx, coordenadora do programa global de combate à AIDS dos EUA e representante especial dos Estados Unidos para a Diplomacia da Saúde Global. "Com meninas e jovens representando 71 por cento de todos os novos casos de infecção pelo HIV entre adolescentes na África Subsaariana, nós precisamos urgentemente de soluções inovadoras que lhes permitam proteger sua saúde e sair em busca de seus sonhos."

"São necessárias novas ideias e abordagens de alto impacto para endereçar as inúmeras complexidades por trás desta urgente crise de saúde", disse Jaak Peeters, diretor da organização de Saúde Pública Global da Johnson & Johnson. "Ao abordar os fatores e complexidades que impactam estas jovens em um nível fundamental, esperamos melhorar de forma mensurável os efeitos na saúde e criar mudanças duradouras. Esses são componentes importantes da abordagem da Johnson & Johnson para a melhoria da saúde pública global."

Como um parceiro importante, a Johnson & Johnson, através de suas empresas farmacêuticas Janssen, uniu-se à Parceria DREAMS em dezembro passado. A ambiciosa parceria no valor de $385 milhões fornece um pacote básico de abordagens baseadas em evidências que vão além do setor da saúde, endereçando os fatores estruturais que direta ou indiretamente elevam o risco da transmissão do HIV em meninas, incluindo pobreza, desigualdade de gêneros, violência sexual e falta de informação. O PEPFAR, a Fundação Bill & Melinda Gates, Girl Effect, Gilead Sciences e ViiV Healthcare também fazem parte da Parceria DREAMS.

Realizando um impacto sustentável na saúde pública global 

O combate ao HIV é um componente importante do duradouro legado da Johnson & Johnson de compromisso e parceria em prol da melhoria da saúde pública global para indivíduos, famílias e comunidades em todo o mundo. Através de sua organização de saúde pública global, a empresa visa oferecer soluções integradas e baseadas em evidências para abordar necessidades abrangentes da saúde e proporcionar um impacto significativo e duradouro em três áreas de foco fundamentais: HIV, saúde da mãe e do filho e tuberculose (TB) extensivamente resistente (XDR) e multirresistente (MDR) a drogas.  

Informações sobre propostas para a iniciativa Desafio em Busca de Inovação DREAMS 

A Parceria DREAMS espera anunciar os vencedores na metade de julho, com a implementação no começo do outono (hemisfério norte) de 2016. Os prêmios variarão de $100.000 a $40 milhões. As soluções devem ser implementadas no Quênia, Lesoto, Malawi, Moçambique, África do Sul, Suazilândia, Tanzânia, Uganda, Zâmbia e Zimbabwe.

Os candidatos devem submeter uma expressão de interesse (EOI) no website do Desafio: www.dreamschallenge.org até 28 de março de 2016, às 23h59min, horário de verão no leste dos EUA. Os pedidos serão revistos e os finalistas serão convidados a submeter uma proposta.

Para mais informações sobre o Desafio ou para se inscrever, acesse o website do Desafio em Busca de Inovação DREAMS, www.dreamschallenge.org. Os candidatos interessados podem baixar o anúncio de oportunidade do Desafio para obter mais detalhes sobre os requisitos, termos e condições.

Sobre a Johnson & Johnson

Cuidar do mundo, uma pessoa de cada vez inspira e une o pessoal da Johnson & Johnson. Nós optamos pela pesquisa e pela ciência – trazendo produtos, serviços e ideias inovadoras para promover a saúde e o bem-estar das pessoas. Aproximadamente 128.000 funcionários em mais de 265 empresas operacionais Johnson & Johnson trabalham com parceiros da área de saúde para fazer a diferença na vida de mais de um bilhão de pessoas todos os dias, em todo o mundo.

FONTE Johnson & Johnson

Related Links

http://www.jnj.com

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

icon3
440k+
Newsrooms &
Influencers
icon1
9k+
Digital Media
Outlets
icon2
270k+
Journalists
Opted In
GET STARTED

Modal title

Also from this source

TREMFYA® (guselkumab) achieves U.S. approval for subcutaneous induction in adults with ulcerative colitis, now the first and only IL-23 inhibitor with a fully subcutaneous regimen

TREMFYA® (guselkumab) achieves U.S. approval for subcutaneous induction in adults with ulcerative colitis, now the first and only IL-23 inhibitor with a fully subcutaneous regimen

Johnson & Johnson (NYSE: JNJ) today announced that the U.S. Food and Drug Administration (FDA) has approved a subcutaneous (SC) induction regimen of...

TECVAYLI® and DARZALEX FASPRO®-based induction treatment demonstrates promising rates and depths of response in transplant-eligible patients with newly diagnosed multiple myeloma

TECVAYLI® and DARZALEX FASPRO®-based induction treatment demonstrates promising rates and depths of response in transplant-eligible patients with newly diagnosed multiple myeloma

Johnson & Johnson (NYSE:JNJ) today announced that an investigational immune-based induction regimen with TECVAYLI® (teclistamab-cqyv) and DARZALEX...

More Releases From This Source

Explore

Health Care & Hospitals

Health Care & Hospitals

Medical Pharmaceuticals

Medical Pharmaceuticals

Pharmaceuticals

Pharmaceuticals

Infection Control

Infection Control

News Releases in Similar Topics

Contact PR Newswire

  • Call PR Newswire at 888-776-0942
    from 8 AM - 9 PM ET
  • Chat with an Expert
  • General Inquiries
  • Editorial Bureaus
  • Partnerships
  • Media Inquiries
  • Worldwide Offices

Products

  • For Marketers
  • For Public Relations
  • For IR & Compliance
  • For Agency
  • All Products

About

  • About PR Newswire
  • About Cision
  • Become a Publishing Partner
  • Become a Channel Partner
  • Careers
  • Accessibility Statement
  • APAC
  • APAC - Simplified Chinese
  • APAC - Traditional Chinese
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Indonesia
  • Israel
  • Italy
  • Japan
  • Korea
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United Kingdom
  • Vietnam

My Services

  • All New Releases
  • Platform
  • ProfNet
  • Data Privacy

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921

Contact PR Newswire

Products

About

My Services
  • All News Releases
  • Platform
  • ProfNet
Call PR Newswire at
888-776-0942
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • RSS
  • Cookies
Copyright © 2025 Cision US Inc.